✦ LIBER ✦

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

✍ Scribed by Nancy U. Lin; Wolfgang Eierman; Richard Greil; Mario Campone; Bella Kaufman; Klaudia Steplewski; Stephen R. Lane; Denise Zembryki; Stephen D. Rubin; Eric P. Winer

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 189 KB
Volume: 105
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-011-0629-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of a novel capecitabine d

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer

✍ Devika Gajria; Joseph Gonzalez; Kimberly Feigin; Sujata Patil; Carol Chen; Maria 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 219 KB

Phase II, double-blind, randomized trial

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

✍ Mark Clemons; Anil A. Joy; Radhi Abdulnabi; Mauricio Kotliar; Jodi Lynch; Johan 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 317 KB

Randomized Phase II Trial of weekly pacl

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

✍ Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivella 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 222 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB